Cofactors
Dietary SupplementOral administration of 1g nicotinamide riboside, 3g L-carnitine, 20g serine and 5g N-acetylcystein, first as single compounds, then combined, on 5 days
NCT Number: NCT03838822
There is a strong correlation between major adverse health consequences of obesity and development of non-alcoholic fatty liver disease (NAFLD). NAFLD is characterized by abnormal hepatic accumulation of triglycerides and other lipids. It has become a worldwide health problem that accelerates cirrhosis, type 2 diabetes mellitus (T2DM), and especially premature cardiovascular morbidity and mortality.
The plasma level of glutathione (GSH) is typically depleted in individuals with metabolism related disorders. However, cellular GSH levels cannot be increased by supplementing GSH and it must be synthesized within the liver either de novo or by salvation pathway. The level of GSH is not enough to maintain and regulate the thiol redox status of the liver in subjects with high hepatic steatosis at fasting stage due to the depletion of glycine. Glycine can be synthesized via the interconversion of serine. It has been shown that the serine synthesis is downregulated in patients with NAFLD and supplementation of serine has attenuated alcoholic fatty liver by enhancing homocysteine metabolism in mice and rats. Depleted liver glutathione is also restored by the administration of N-acetylcystein as in acetaminophen poising. L-carnitine and nicotinamide that both stimulate the transfer of fatty acids from cytosol to mitochondria have been identified as two additional cofactors that are depleted in patients with NAFLD.
In this study, the kinetics in blood of pivotal metabolic cofactors, serine, L-carnitine, N-acetylcystein and nicotinamide after single and simultaneous dietary supplementation, are measured.
Looking for future studies?
Notify Me18 year–40 year
Male
Interventional
Early Phase 1
Hanns-Ulrich Marschall, Gothenburg, Sweden
In 10 healthy subjects with BMI <30 kg/m2 the plasma concentrations of 4 natural compounds (nicotinamide riboside, L-carnitine, L-serine and N-acetylcystein) are measured by ultra-performance liquid chromatography-tandem mass spectrometry (UPLCMSMS) after individual and combined administration, on five consecutive days and at every hour during 9 hours after administration. The study will start at 8:00 every morning and at each time point, blood samples will be collected.
The taste and any potential sensing of the co-factors such as vertigo, nausea, bowel movement will be recorded.
Each participant will receive one oral dose of Day 1: 1 g nicotinamide riboside; Day 2: 3 g L-carnitine; Day 3: 5 g N-acetylcystein; Day 4: 20 g L-serine; Day 5: combined 1 g nicotinamide riboside, 3 g L-carnitine, 5 g N-acetylcystein, and 20 g L-serine
In addition, untargeted metabolomics analysis as well as O-link proteomics analysis we be performed to study effect of the administered cofactors.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Healthy without any medication, no smokers, no obesity
Exclusion criteria
Any known disease, obesity
Oral administration of 1g nicotinamide riboside, 3g L-carnitine, 20g serine and 5g N-acetylcystein, first as single compounds, then combined, on 5 days
Time frame: Twenty-four hours after administration
Plasma levels of nicotinamide riboside by UPLCMSMS at 8 time points during 24h after administration
Time frame: Twenty-four hours after administration
Plasma levels of L-carnitine (nM) measured by UPLCMSMS at 8 time points during 24h after administration
Time frame: Twenty-four hours after administration
Plasma levels of L-serine (nM) measured by UPLCMSMS at 8 times points during 24h after administration
Time frame: Twenty-four hours after administration
Plasma levels of N-acetylcystein (nM) measured by UPLCMSMS at 8 times points during 24h after administration
Time frame: Twenty-four hours after administration of combined cofactors
Untargeted metabolomic analysis using mass spectrometry. (Untargeted = not pre-specified in terms of outcome)
Time frame: Twenty-four hours after administration of combined cofactors
Changes in the plasma level of inflammation related proteins associated with the supplementation of metabolic co-factors.
Sahlgrenska University Hospital
Other
Kinetics of Metabolic Cofactors After Oral Supplementation in Healthy Subjects
Acronym: NAFLDCOFCAL
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details